Eulexin

Known as: Drogenil, Euflex, Eulexine 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1986-2017
024619862017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
OBJECTIVE To compare parenteral estrogen therapy in the form of high-dose polyestradiol phosphate (PEP; Estradurin) with combined… (More)
Is this relevant?
2002
2002
OBJECTIVE In the mid-1980s, interest in parenteral estrogen therapy for prostate cancer was renewed when it was found that it… (More)
Is this relevant?
1999
1999
Our earlier report suggested that androst-5-ene-3beta,7beta-diol (Delta(5)-androstenediol or Adiol) is a natural hormone with… (More)
Is this relevant?
1998
1998
OBJECTIVES To assess whether flutamide (Drogenil), a pure androgen receptor blocking agent, improves survival in patients with… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
1998
1998
It is known that androst-5-ene-3beta,17beta-diol (Adiol), a precursor of testosterone (T), can activate estrogen target genes… (More)
Is this relevant?
1997
1997
Evolving data suggest that palliation of relapsed prostate cancer can be achieved by the selective discontinuation of agents that… (More)
Is this relevant?
1997
1997
OBJECTIVES A combination of flutamide (Eulexin) or nilutamide (Anandron) with a luteinizing hormone-releasing hormone (LHRH… (More)
Is this relevant?
1994
1994
PURPOSE To determine the extent of reduction of volume of normal tissue structures exposed to high doses of radiation therapy (RT… (More)
Is this relevant?
1989
1989
A case of severe toxic hepatitis in a patient with metastatic prostatic cancer treated for three months with flutamide (Eulexin… (More)
Is this relevant?
1986
1986
Chronic treatment of adult men with LHRH agonists causes a decrease in serum testosterone and 5 alpha-dihydrotestosterone to… (More)
Is this relevant?